Larson Financial Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $89.2K | Buy |
710
+310
| +78% | +$39K | ﹤0.01% | 884 |
|
|
2025
Q1 | $44.2K | Sell |
400
-1,013
| -72% | -$112K | ﹤0.01% | 1069 |
|
|
2024
Q4 | $193K | Buy |
1,413
+12
| +0.9% | +$1.64K | 0.01% | 569 |
|
|
2024
Q3 | $161K | Sell |
1,401
-492
| -26% | -$56.7K | 0.01% | 622 |
|
|
2024
Q2 | $261K | Sell |
1,893
-320
| -14% | -$44.1K | 0.02% | 397 |
|
|
2024
Q1 | $305K | Sell |
2,213
-44
| -2% | -$6.07K | 0.02% | 312 |
|
|
2023
Q4 | $297K | Buy |
2,257
+2,246
| +20,418% | +$296K | 0.03% | 273 |
|
|
2023
Q3 | $1.24K | Buy |
+11
| New | +$1.24K | ﹤0.01% | 1454 |
|
|
2023
Q1 | – | Sell |
-2,331
| Closed | -$278K | – | 1581 |
|
|
2022
Q4 | $278K | Buy |
2,331
+391
| +20% | +$46.7K | 0.03% | 257 |
|
|
2022
Q3 | $206K | Buy |
1,940
+122
| +7% | +$13K | 0.03% | 267 |
|
|
2022
Q2 | $177K | Buy |
+1,818
| New | +$177K | 0.03% | 204 |
|